Ratio Therapeutics Inc, a US-based pharmaceutical company that deals with the development of targeted radiotherapeutics for the treatment of cancer, announced on Monday that it has named Dr Noel Monks as its head of biology.

Dr Monks has more than 20 years of experience in drug discovery, development, and translational medicine in the fields of oncology and rare diseases. He has served as senior director of Preclinical Biology and Pharmacology at NeuBase Therapeutics and associate director at AstraZeneca/Medimmune.

Dr John Babich, Ratio's president and chief scientific officer, said: "We are thrilled to welcome Noel to our growing team of world-class experts in radiopharmaceuticals discovery and development. Noel's experience with preclinical drug discovery and development will be instrumental to advancing Ratio's pipeline candidates to clinical studies. His expertise will help us develop further our proprietary radiotherapeutic platforms, Trillium and Macropa, and create new partnerships with pharmaceutical companies in the cancer therapy space."